Summary We studied all cases presenting during life with carcinoma of the bronchus and registered at the Yorkshire Regional Cancer Registry [1976][1977][1978][1979][1980][1981][1982][1983]. During this period fibreoptic bronchoscopy became more widely available in the region, and multiple drug chemotherapy became first line treatment for small cell carcinoma. Although there was little change in the overall incidence of lung cancer during the study period, the proportion of females increased by 4.8% and the mean age at presentation rose by 2.3 years. The histological confirmation rate rose by 29% from 45% to 58%. The proportion of patients with small cell carcinoma treated by chemotherapy increased from 17% to 39%. With this exception therapeutic intervention rates were unaltered. The prognosis of patients with small cell carcinoma treated by chemotherapy improved, particularly so for those less than 60 years. There was a consistent trend for an overall improvement in survival in other groups, and this was significant for those aged 70 and over where it appeared to be related to more appropriate management of squamous cell carcinoma. We conclude from this regional study that increased diagnostic activity in District General Hospitals has allowed an improvement in prognosis both for patients with small cell carcinoma treated by chemotherapy, and in patients over 70 with non-small cell cancer. These trends can be expected to continue over the next few years.
In the 1970s there were two major developments in the management of lung cancer. First, fibreoptic bronchoscopy became more widely available (Simpson et al., 1986) , and second, chemotherapy was established as first-line treatment for patients with small cell lung cancer (MRC Lung Cancer Working Party, 1979) .
Fibreoptic bronchoscopy is now routinely available to 91% of chest physicians, and is available in 88% of district hospitals in England and Wales 'Muers et al., 1988 ; BTS Working Party of the Regional Representatives Committee, 1987) . Grant (1986) has questioned the justification of this investigation in elderly patients with a clinical diagnosis of carcinoma, but Knox ct al. (1988) and Macfarlane et al. (1981) have shown its value in those over the age of 80. However, it is not known whether fibreoptic bronchoscopy has produced a detectable change in the treatment practice or patient survival in the general population, as opposed to individual specialist centres.
Treatment of small cell carcinoma with chemotherapy has increased as controlled trials have shown an improvement in survival, with an extension of life of about 6-12 months in responders (Green et al., 1969; MRC Lung Cancer Working Party, 1983; Souhami et al., 1984) . However, because these controlled trials have usually been performed in centres with a particular interest in chemotherapy, it is not known whether the prognosis of routinely treated patients has improved.
It is well known that the average age at presentation with lung cancer is rising (Coggan & Acheson, 1983 58.4% in 1983 (Figure 2) , and the mean age of confirmed cases rose progressively from 62.9 to 65.8 years ( Figure 2 ). Although small cell carcinoma was somewhat more prevalent in younger patients, representing about one-third of those under 60, and only a quarter of those aged 70 or more, the overall ratio of small cell to squamous cell remained about 3:7 throughout the period (Figure 3 ).
The increased diagnostic activity with an increasing mean age of those histologically confirmed, resulted in the number of patients known to have squamous cell carcinoma increasing by 47% from 484 in 1976 to 712 in 1983, with an increase of 2.9 years in their mean age.
Similarly the numbers known to have small cell carcinoma also increased by 47% from 209 to 308 with an increase of 3.9 years in the mean age. The increase in the numbers of histologically confirmed cases was largely in those aged 70 and over for squamous cell carcinoma and 60 or over the small cell carcinoma, with little change in the histological confirmation rate below the age of 60. Small cell carcinoma Figure 4 shows the survival curves for all the cases of small cell carcinoma, by year, 1976-1983 . It can be seen that the prognosis to 9 months showed a considerable improvement during the period.
The reason for this is seen in Table I , which shows the number and proportion of patients treated with chemotherapy. As this proportion increased, so the prognosis improved, with a particularly large change in median survival between 1979 and 1980, and an overall improvement in the percentage of patients surviving to 9 months. The survival difference lessened subsequently, but most long-term survivors had been treated with chemotherapy. Figure 5 shows the survival to 9 months for the years 1980-1983 of three different age cohorts: <60 years, 60-69 years, and >,70 years. Better survival after chemotherapy than radiotherapy was seen in patients under 60, but there was no such difference in the older patients. As expected, the prognosis of older treated patients was worse than the younger, and approached the 'no treatment' group in the (range 14-25) . Fifteen (11%) of the operated cases were alive at 2 years. The 2-year survival of the small cell carcinoma patients improved from 2% to 8% between 1976 and 1983 (P = 0.004). These patients had been treated by chemotherapy or, occasionally, by surgery.
Other confirmed histological groups These remained about 17% of the total throughout the period. The 2-year survival varied between 7.1% and 11.7% with no consistent trend. Within this number we found no evidence of a significant increase in adenocarcinomas identified during the 8-year period studied. Likewise, there was no significant trend in the prognosis of these tumours.
Histologically non-confirmed There was no change in the poor prognosis of these patients in the study period. The 2-year survival was about 4% throughout. This poor prognosis suggests that the majority were indeed lung cancer, despite the absence of histological confirmation. The number given chemotherapy without a confirmed diagnosis fell from 98 (7.6%) in 1976 to 32 (3.1%) in 1983. Survival of the whole population with lung cancer Examination of the 2-year survival data for the whole population ( Figure 6 ) confirms a trend to improved prognosis between 1976 and 1983. For the patients over 70 P for the trend is 0.0 12 and for those under 60 P = 0.057. The impact of an active treatment policy for patients over 70 is seen in Figure 7 , where the trend to improved survival is highly significant (P = 0.01). 5.00 1976 1977 1978 1979 1980 1981 1982 1983 Years Figure 7 Percentage of 2-year survival for all cases presenting over age 70 years: upper curve actively treated patients; lower curve symptomatic treatment.
Epidemiology
The rise we noted in the mean age at presentation of patients with lung cancer and the rise in the percentage of female patients are similar to trends now well recognised and reflect changing patterns of cigarette smoking established 20 years ago (Coggon & Acheson, 1983; Edinburgh Lung Cancer Group, 1987; Hande & Des Prez, 1983) . Although small cell carcinoma is known to be more common among younger patients (Edinburgh Lung Cancer Group, 1987) , and we confirm this, the increase in mean age of our population was not accompanied by a significant proportional change in the small cell/squamous ratio. Thus we have no evidence so far that small cell carcinoma is becoming a significantly rarer tumour in Britain at the present time; conversely, a higher rate of histological diagnosis is likely to identify increasing numbers.
Histological verification
The particular reason for histological verification is first to allow correct information to be given to patients, second to allow a more accurate prognosis, and third to allow more appropriate therapy. Fibreoptic bronchoscopy can also be used to assess operability, and its use has been parallelled by a fall in the rate and availability of rigid bronchoscopy in the UK (British Thoracic Society, 1987; Muers et al., 1988) . In our study, the effect of this activity was to raise the rate of histological confirmation by 29% over the 6-year period, from 45% to 58% of all cases. This is still a lower rate than in smaller series from other centres, such as Edinburgh (Edinburgh Lung Cancer Group, 1987 
Small cell carcinoma
The benefits shown in controlled trials of treatment with chemotherapy (Green et al., 1969; MRC Lung Cancer Working Party, 1979 Souhami et al., 1984) are now being reflected in the survival experience of patients throughout our region. Survival to 9 months, but not the median survival, has increased (Table I) . This seems to be because more patients well enough for treatment are having chemotherapy, but the untreated, probably older, patients have a very bad prognosis. It is well recognised that the effect of chemotherapy for small cell lung cancer has reached a plateau (Klastersky, 1988) and there may not be a further increase in survival now for some time, although chemotherapy regimens may be simplified and better use of prognostic factors may limit treatment to those destined to survive long enough to show such benefit (Vincent et al., 1987) .
Methods
Registry data was used for this analysis. We recognise that the registry does not hold records for all patients with lung cancer in Yorkshire, but comparison of the registry figures with the standardised incidence rates from the OPCS (1979, 1981) revealed that the Registry data recorded a higher than expected rate for males, and the expected rate for females (YRCO, 1985) . This is evidence that the Registry holds a largely complete record of bronchial carcinoma in the Yorkshire region. Our (Grant, 1986) . This study amply justifies the increased diagnostic activity, as the principal beneficiaries of the change in practice in the years of the study were patients with squamous cell carcinoma aged 70 or over. The rate of surgical intervention in squamous cell carcinoma as a whole was little changed despite the increases in age, and survival was not compromised. There is no support in the figures here for the view that a patient should not be operated upon over the age of 70.
Conclusion
This cancer registry study has shown modest improvements in prognosis in some groups of patients with lung carcinoma as a result of the application of modern methods of diagnosis and treatment. There are grounds for the belief that these f'% nn trends will continue as the techniques become even more widely available and applied within District General Hospitals in Britian. Our findings support the view that there is a need for all patients with carcinoma of the lung to be referred to respiratory physicians for full evaluation and advice about appropriate management.
